Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly-ICLC and IVIG with ICIs for Advanced NSCLC
NCT06064279Phase 2Withdrawn
- Sponsor
- VA Office of Research & Development
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poly iclc in non-small cell lung cancer (NSCLC), sponsored by VA Office of Research & Development. Primary endpoints: Maximum Tolerated Dose at 10 months, Dose Limiting Toxicity at 10 months and 1 more. Planned start Jun 2024; status: withdrawn.
02
Drugs
poly iclc
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06064279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06064279.